Povetacicept Demonstrates Efficacy in Phase 3 Trial for IgA Nephropathy

Vertex Pharmaceuticals announced that Phase 3 RAINIER trial results for povetacicept in IgA nephropathy were published in The New England Journal of Medicine. The study showed a 52.0% reduction in proteinuria from baseline at Week 36 and a statistically significant 49.8% reduction versus placebo, along with a favorable safety profile. This data suggests a potential new treatment option for the condition.